Evidence map›Paper›PMID 41148790›Full record

ArticleCells2025

Biomarker-Based Pharmacological Characterization of ENX-102, a Novel α2/3/5 Subtype-Selective GABAA Receptor Positive Allo-Steric Modulator: Translational Insights from Rodent and Human Studies.

Pauline Nettesheim, Krishna C Vadodaria, Kimberly E Vanover, Laura G J M Borghans, Estibaliz Arce, William Brubaker, Stephen Cunningham, Stephanie Parks, Jordi Serrats, Vikram Sudarsan and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Pauline NettesheimCentre for Human Drug Research, 2333 CL Leiden, The Netherlands.
Krishna C VadodariaEngrail Therapeutics, Inc., San Diego, CA 92130, USA.ORCID 0000-0002-3455-0209
Kimberly E VanoverEngrail Therapeutics, Inc., San Diego, CA 92130, USA.
Laura G J M BorghansCentre for Human Drug Research, 2333 CL Leiden, The Netherlands.
Estibaliz ArceEngrail Therapeutics, Inc., San Diego, CA 92130, USA.
William BrubakerEngrail Therapeutics, Inc., San Diego, CA 92130, USA.
Stephen CunninghamEngrail Therapeutics, Inc., San Diego, CA 92130, USA.
Stephanie ParksEngrail Therapeutics, Inc., San Diego, CA 92130, USA.
Jordi SerratsEngrail Therapeutics, Inc., San Diego, CA 92130, USA.
Vikram SudarsanEngrail Therapeutics, Inc., San Diego, CA 92130, USA.
Eve TaylorEngrail Therapeutics, Inc., San Diego, CA 92130, USA.
Erica KlaassenCentre for Human Drug Research, 2333 CL Leiden, The Netherlands.
Frederik E StuurmanDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZG Leiden, The Netherlands.ORCID 0000-0002-0013-8355
Gabriel E JacobsCentre for Human Drug Research, 2333 CL Leiden, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gamma-aminobutyric acid type A receptors (GABA

Indexed as

Anti-Anxiety AgentsReceptors, GABA-AAdultAnimalsBiomarkersDouble-Blind MethodElectroencephalographyFemaleHumansMaleMiceRatsRats, Sprague-DawleyTranslational Research, BiomedicalYoung AdultAnti-Anxiety AgentsBiomarkersReceptors, GABA-AbenzodiazepineENX-102GABAA receptorsubtype-selectivetranslational

Identifiers

PMID41148790
PMCPMC12564412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.